Premium
Valaciclovir as a single dose during prodrome of herpes facialis: a pilot randomized double‐blind clinical trial
Author(s) -
Chosidow O.,
Drouault Y.,
Garraffo R.,
Veyssier P.
Publication year - 2003
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.2003.05062.x
Subject(s) - valaciclovir , medicine , randomized controlled trial , prodrome , placebo , population , surgery , clinical trial , viral disease , herpesviridae , virus , alternative medicine , environmental health , psychosis , virology , pathology , psychiatry
Summary Background Randomized clinical trials of valaciclovir in recurrent herpes labialis are lacking. Objectives To determine whether a single course of valaciclovir, i.e. 500, 1000 or 2000 mg, administered during the prodrome of herpes facialis, could be beneficial. Methods Three hundred and forty‐five out‐patients with herpes labialis were screened and randomized for a multicentre, double‐blind clinical trial. Ninety‐six patients had no recurrence after 6 months of follow‐up; 249 patients were finally included in the intent‐to‐treat (ITT) population. The main outcome measure was the rate of aborted episodes at day 3. The three treatment groups were similar at baseline. Results There was no statistically significant difference between the groups in rates of aborted lesions at day 3 in the ITT population, in particular between the 500 mg and 2000 mg treatment groups. Conclusions Although a placebo group was not included in this pilot study, a single dose of valaciclovir was not considered beneficial in patients with recurrent herpes facialis.